CN107427485B - 用于治疗焦虑症的中链脂肪酸及其甘油三酯 - Google Patents
用于治疗焦虑症的中链脂肪酸及其甘油三酯 Download PDFInfo
- Publication number
- CN107427485B CN107427485B CN201680010905.4A CN201680010905A CN107427485B CN 107427485 B CN107427485 B CN 107427485B CN 201680010905 A CN201680010905 A CN 201680010905A CN 107427485 B CN107427485 B CN 107427485B
- Authority
- CN
- China
- Prior art keywords
- product
- anxiety
- disorder
- use according
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract description 107
- 150000004667 medium chain fatty acids Chemical class 0.000 title claims abstract description 42
- 150000003626 triacylglycerols Chemical class 0.000 title description 6
- 230000002265 prevention Effects 0.000 claims abstract description 11
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 59
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 49
- 239000000203 mixture Substances 0.000 claims description 48
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 37
- 229960002446 octanoic acid Drugs 0.000 claims description 27
- 235000013305 food Nutrition 0.000 claims description 24
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 22
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 12
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 10
- 235000013365 dairy product Nutrition 0.000 claims description 10
- 150000004665 fatty acids Chemical group 0.000 claims description 10
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 10
- 206010041250 Social phobia Diseases 0.000 claims description 9
- 208000019906 panic disease Diseases 0.000 claims description 9
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 8
- 206010034912 Phobia Diseases 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 7
- 208000019899 phobic disease Diseases 0.000 claims description 7
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims description 6
- 235000019197 fats Nutrition 0.000 claims description 6
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 6
- 235000011962 puddings Nutrition 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 235000013351 cheese Nutrition 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 235000004213 low-fat Nutrition 0.000 claims description 4
- 235000015173 baked goods and baking mixes Nutrition 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 235000014121 butter Nutrition 0.000 claims description 3
- 235000019219 chocolate Nutrition 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 235000021185 dessert Nutrition 0.000 claims description 3
- 235000021001 fermented dairy product Nutrition 0.000 claims description 3
- 235000019541 flavored milk drink Nutrition 0.000 claims description 3
- 235000015243 ice cream Nutrition 0.000 claims description 3
- 235000015110 jellies Nutrition 0.000 claims description 3
- 239000008274 jelly Substances 0.000 claims description 3
- 235000013310 margarine Nutrition 0.000 claims description 3
- 239000003264 margarine Substances 0.000 claims description 3
- 239000008268 mayonnaise Substances 0.000 claims description 3
- 235000010746 mayonnaise Nutrition 0.000 claims description 3
- 239000007764 o/w emulsion Substances 0.000 claims description 3
- 235000014059 processed cheese Nutrition 0.000 claims description 3
- 235000013618 yogurt Nutrition 0.000 claims description 3
- 230000036506 anxiety Effects 0.000 abstract description 61
- 241000700159 Rattus Species 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 19
- 238000012360 testing method Methods 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 12
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 9
- 102000009433 Insulin Receptor Substrate Proteins Human genes 0.000 description 9
- 108010034219 Insulin Receptor Substrate Proteins Proteins 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 150000002576 ketones Chemical class 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 230000006399 behavior Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 208000004044 Hypesthesia Diseases 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 206010038743 Restlessness Diseases 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 208000034783 hypoesthesia Diseases 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 231100000862 numbness Toxicity 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 230000003997 social interaction Effects 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 101000987117 Homo sapiens Monocarboxylate transporter 8 Proteins 0.000 description 3
- 208000008454 Hyperhidrosis Diseases 0.000 description 3
- 102100021425 Monocarboxylate transporter 10 Human genes 0.000 description 3
- 102100027871 Monocarboxylate transporter 8 Human genes 0.000 description 3
- 206010049816 Muscle tightness Diseases 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 108091006608 SLC16A10 Proteins 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000009429 distress Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000002361 ketogenic effect Effects 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 210000001009 nucleus accumben Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 201000001716 specific phobia Diseases 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 108700019745 Disks Large Homolog 4 Proteins 0.000 description 1
- 102000047174 Disks Large Homolog 4 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000969630 Homo sapiens Monocarboxylate transporter 10 Proteins 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041247 Social fear Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 230000007000 age related cognitive decline Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000019463 artificial additive Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 238000009225 cognitive behavioral therapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008918 emotional behaviour Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 125000005473 octanoic acid group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 108091005981 phosphorylated proteins Proteins 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000003989 repetitive behavior Effects 0.000 description 1
- 208000013406 repetitive behavior Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 230000004036 social memory Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/01—Other fatty acid esters, e.g. phosphatides
- A23D7/013—Spread compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
- A23D9/013—Other fatty acid esters, e.g. phosphatides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/50—Feeding-stuffs specially adapted for particular animals for rodents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Birds (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- General Preparation And Processing Of Foods (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15155852.5 | 2015-02-20 | ||
EP15155852 | 2015-02-20 | ||
PCT/EP2016/052079 WO2016131640A1 (en) | 2015-02-20 | 2016-02-01 | Medium chain fatty acids and their triglycerides for treating anxiety |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107427485A CN107427485A (zh) | 2017-12-01 |
CN107427485B true CN107427485B (zh) | 2021-06-18 |
Family
ID=52686085
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680010905.4A Active CN107427485B (zh) | 2015-02-20 | 2016-02-01 | 用于治疗焦虑症的中链脂肪酸及其甘油三酯 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10596137B2 (enescription) |
EP (1) | EP3259029B1 (enescription) |
JP (1) | JP6669761B2 (enescription) |
CN (1) | CN107427485B (enescription) |
AU (1) | AU2016221929A1 (enescription) |
CA (1) | CA2974867A1 (enescription) |
ES (1) | ES2832777T3 (enescription) |
WO (1) | WO2016131640A1 (enescription) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108289873A (zh) * | 2015-12-04 | 2018-07-17 | 雀巢产品技术援助有限公司 | 用于改善认知的方法 |
CN108653374A (zh) * | 2018-07-13 | 2018-10-16 | 安徽松山堂国药股份有限公司 | 一种能够有效促进睡眠的药物组合物 |
JP2020083852A (ja) * | 2018-11-30 | 2020-06-04 | 株式会社明治 | ストレス性疾患予防組成物 |
CN109805108B (zh) * | 2019-03-29 | 2021-04-23 | 江南大学 | 一种炎性肠病特殊医学用途配方食品脂肪组件及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1291093A (zh) * | 1998-01-21 | 2001-04-11 | 菲德利尼公司 | 可减轻应激、焦虑和进攻性的猪平息信息素 |
CN1668318A (zh) * | 2002-06-19 | 2005-09-14 | 菲德利尼公司 | 减轻应激、焦虑和进攻性的禽平息信息素 |
WO2013186570A1 (en) * | 2012-06-15 | 2013-12-19 | Vitaflo (International) Ltd | Nutritional product |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2457567B1 (en) | 2007-09-19 | 2015-12-30 | Nagoya Industrial Science Research Institute | Agent having neurotrophic factor-like activity |
-
2016
- 2016-02-01 US US15/551,094 patent/US10596137B2/en active Active
- 2016-02-01 WO PCT/EP2016/052079 patent/WO2016131640A1/en active Application Filing
- 2016-02-01 JP JP2017539441A patent/JP6669761B2/ja active Active
- 2016-02-01 AU AU2016221929A patent/AU2016221929A1/en not_active Abandoned
- 2016-02-01 EP EP16703463.6A patent/EP3259029B1/en active Active
- 2016-02-01 CN CN201680010905.4A patent/CN107427485B/zh active Active
- 2016-02-01 ES ES16703463T patent/ES2832777T3/es active Active
- 2016-02-01 CA CA2974867A patent/CA2974867A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1291093A (zh) * | 1998-01-21 | 2001-04-11 | 菲德利尼公司 | 可减轻应激、焦虑和进攻性的猪平息信息素 |
CN1668318A (zh) * | 2002-06-19 | 2005-09-14 | 菲德利尼公司 | 减轻应激、焦虑和进攻性的禽平息信息素 |
WO2013186570A1 (en) * | 2012-06-15 | 2013-12-19 | Vitaflo (International) Ltd | Nutritional product |
Non-Patent Citations (4)
Title |
---|
Antidepressant-Like Activity of 10-Hydroxy-Trans-2-Decenoic Acid, a Unique Unsaturated Fatty Acid of Royal Jelly,in Stress-Inducible Depression-Like Mouse Model;Satoru Ito et al;《Evidence-Based Complementary and Alternative Medicine》;20120101;标题、摘要、figure1 * |
Anxiolytic-like effect of trans-2-decenoic acid ethyl ester in stress-induced anxiety-like model mice;AKihisa Makino et al;《Biomedical Research》;20130101;第34卷(第5期);标题、摘要、fig.1 * |
Anxiolytic-like effects of human amniotic fluid and its fatty acids in wistar rats;Carlos M. Contrerasa et al;《Behavioural Pharmacology》;20111031;第22卷(第7期);第655页标题、摘要 * |
Carlos M. Contrerasa et al.Anxiolytic-like effects of human amniotic fluid and its fatty acids in wistar rats.《Behavioural Pharmacology》.2011,第22卷(第7期),655-662. * |
Also Published As
Publication number | Publication date |
---|---|
US10596137B2 (en) | 2020-03-24 |
CN107427485A (zh) | 2017-12-01 |
AU2016221929A1 (en) | 2017-07-13 |
US20180028479A1 (en) | 2018-02-01 |
WO2016131640A1 (en) | 2016-08-25 |
EP3259029A1 (en) | 2017-12-27 |
ES2832777T3 (es) | 2021-06-11 |
EP3259029B1 (en) | 2020-10-21 |
JP6669761B2 (ja) | 2020-03-18 |
CA2974867A1 (en) | 2016-08-25 |
JP2018511558A (ja) | 2018-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023100665A (ja) | 栄養製品 | |
US9326956B2 (en) | Methods for improving brain development and cognitive function using beta-hydroxy-beta methylbutyrate | |
JP6609555B2 (ja) | 脳機能改善剤、及び認知機能障害の予防または治療剤 | |
US9895375B2 (en) | Compositions containing riboflavin and sesamin-class compounds | |
CN107427485B (zh) | 用于治疗焦虑症的中链脂肪酸及其甘油三酯 | |
JP2021176333A (ja) | 桂皮アルデヒド及び亜鉛を含む組成物並びにかかる組成物の使用方法 | |
Sharma et al. | Non-pharmacological treatments for ADHD in youth | |
US20220305020A1 (en) | The use of paraxanthine to reduce exercise-induced mental fatigue | |
US10092028B2 (en) | Compositions comprising cinnamaldehyde and zinc and methods of using such compositions | |
JP6360172B2 (ja) | チグリンアルデヒドを使用する組成物及び方法 | |
WO2021212700A1 (zh) | 一种改善宠物晕车的药物组合物及其制备方法和使用方法 | |
Thomas et al. | Neurocognitive Developmental Outcomes in Early Adolescent Rats Prenatally Exposed to Choline and Docosahexaenoic Acid. | |
JP2006176421A (ja) | ニンニク卵黄を含有する脳機能及び/又は血液流動性改善用組成物 | |
WO2018207921A1 (ja) | 総ケトン体濃度上昇剤、油脂組成物、医薬組成物、食品組成物 | |
JP2005348720A (ja) | 精神安定用飲食品及び飼料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190716 Address after: Vevey Applicant after: SOCIETE DES PRODUITS NESTLE S. A. Address before: Vevey Applicant before: Nestle Products Technical Assistance Co., Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |